Maintenance Therapy with XXXX after Allogeneic Stem Cell Transplantation for @entity3052 and @entity2590 .

@entity1 @entity137 @entity66 @entity5 @entity2590 @entity3052 @entity1778 @entity2132 @entity403 @entity11508
@entity11508 is a hypomethylating agent that irreversibly inhibits DNA methyltransferase I, inducing leukemic differentiation and re-expression of epigenetically silenced putative @entity5 antigens. We assessed safety and efficacy of @entity11508 maintenance after allogeneic transplantation for @entity3052 ( @entity3052 ) and @entity2590 ( @entity2590 ). @entity11508 maintenance may help eradicate minimal @entity66 , decrease the incidence of @entity2132 ( @entity2132 ), and facilitate a graft-versus- @entity1778 effect by enhancing the effect of T regulatory lymphocytes. @entity1 with @entity3052 / @entity2590 in complete remission (CR) after allotransplantation started @entity11508 between day +50 and +100. We investigated 4 @entity11508 doses in cohorts of 4 @entity1 : 5, 7.5, 10, and 15 mg/m(2)/day * 5 days every 6 weeks, for a maximum 8 cycles. The maximum tolerated dose (MTD) was defined as the maximum dose at which  <= 25% of @entity1 experience dose-limiting @entity137 during the first cycle of treatment. Twenty-four @entity1 were enrolled and 22 were evaluable. All 4 dose levels were completed and no MTD was reached. Overall, @entity11508 maintenance was well tolerated. Grade 3 and 4 hematological @entity137 were experienced by 75% of @entity1 , including all @entity1 treated at the highest dose level. Nine @entity1 completed all 8 cycles and 8 of them remain in CR. Nine @entity1 died from relapse (n = 4), infectious complications (n = 3), and @entity2132 (n = 2). Most occurrences of acute @entity2132 were mild and resolved without interruption of treatment; 1 @entity1 died of acute gut @entity2132 . @entity11508 maintenance did not clearly impact the rate of chronic @entity2132 . Although there was a trend of increased @entity403 expression, results were not statistically significant. In conclusion, @entity11508 maintenance is associated with acceptable @entity137 when given in the post-allotransplantation setting. Although the MTD was not reached, the dose of 10 mg/m(2) for 5 days every 6 weeks appeared to be the optimal dose rather than 15 mg/m(2), where most hematological @entity137 occurred.
